 6. Patients must have recovered from all toxicities related to prior anticancer therapies to grade 2 CTCAE v 4.03, provided that concomitant medication is given prior to initiation of treatment with LDK378. Exception to this criterion: patients with any grade of alopecia are allowed to enter the treatment. 